biostudies-literatureUnknown13Li X<h4>Purpose</h4>To evaluate the outcomes and prognostic factors for patients using conversion therapy with lenvatinib combined with transcatheter arterial chemoembolization (TACE) plus programmed cell death protein-1 (PD-1) inhibitors (LTP) for initially unresectable hepatocellular carcinoma (iuHCC).<h4>Methods</h4>Data on 94 consecutive patients with iuHCC who received LTP conversion therapy from November 2019 to September 2022 were retrospectively analyzed. Early tumor response was reported when patients showed complete or partial response at the time of their first follow-up (4-6 weeks) after initial treatment, in accordance with mRECIST. The endpoints consisted of conversion surgery rate, overall survival (OS), and progression-free survival (PFS).<h4>Results</h4>Early tumor response waFrontiers in oncology1110689https://www.ebi.ac.uk/biostudies/studies/S-EPMC9923097biostudies-literatureOutcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.PMC9923097Li XBai TTang ZHuang CChen JWei TLu SLiu BWang XZhang BLi LWu FfalseOutcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.<h4>Purpose</h4>To evaluate the outcomes and prognostic factors for patients using conversion therapy with lenvatinib combined with transcatheter arterial chemoembolization (TACE) plus programmed cell death protein-1 (PD-1) inhibitors (LTP) for initially unresectable hepatocellular carcinoma (iuHCC).<h4>Methods</h4>Data on 94 consecutive patients with iuHCC who received LTP conversion therapy from November 2019 to September 2022 were retrospectively analyzed. Early tumor response was reported when patients showed complete or partial response at the time of their first follow-up (4-6 weeks) after initial treatment, in accordance with mRECIST. The endpoints consisted of conversion surgery rate, overall survival (OS), and progression-free survival (PFS).<h4>Results</h4>Early tumor response wa2023-01-01T00:00:00Z20232025-04-05T10:36:22.871Z2025-04-05T10:36:22.871ZS-EPMC99230973679361410.3389/fonc.2023.1110689